MXPA04001812A - Nueva forma de dosificacion oral de liberacion prolongada. - Google Patents
Nueva forma de dosificacion oral de liberacion prolongada.Info
- Publication number
- MXPA04001812A MXPA04001812A MXPA04001812A MXPA04001812A MXPA04001812A MX PA04001812 A MXPA04001812 A MX PA04001812A MX PA04001812 A MXPA04001812 A MX PA04001812A MX PA04001812 A MXPA04001812 A MX PA04001812A MX PA04001812 A MXPA04001812 A MX PA04001812A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- extended release
- release oral
- oral dosage
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una forma de dosificacion oral, de liberacion prolongada, de una sustancia farmaceuticamente activa, (R) - 3 -N, N- diciclobutilamino- 8 - fluoro-3,4-dihidro-2H-1-benzopiran-5-carboxamida, en la forma de una base libre o sales farmaceuticamente aceptables y/o hidratos o solvatos de la misma. Ademas, la invencion se refiere a una forma de dosificacion oral, de liberacion prolongada, que proporciona un perfil de concentracion sanguineo definido, que no tiene un aumento inicial rapido en la concentracion del plasma de dicha sustancia activa cuando se administra en dosis bajas. La invencion se refiere ademas, a un proceso para preparar dicha forma de dosificacion, el uso de dicha forma de dosificacion y un metodo para la prevencion y/o tratamiento de las trastornos del SNC y alteraciones medicas relacionadas que usan dicha forma de dosificacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102886A SE0102886D0 (sv) | 2001-08-29 | 2001-08-29 | New formulation |
| PCT/SE2002/001540 WO2003017982A1 (en) | 2001-08-29 | 2002-08-28 | A new extended release oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04001812A true MXPA04001812A (es) | 2004-07-08 |
Family
ID=20285177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04001812A MXPA04001812A (es) | 2001-08-29 | 2002-08-28 | Nueva forma de dosificacion oral de liberacion prolongada. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040204482A1 (es) |
| EP (1) | EP1423098A1 (es) |
| JP (1) | JP2005504051A (es) |
| KR (1) | KR20040032976A (es) |
| CN (1) | CN1547466A (es) |
| BR (1) | BR0212166A (es) |
| CA (1) | CA2457339A1 (es) |
| HU (1) | HUP0401587A3 (es) |
| IL (1) | IL160372A0 (es) |
| MX (1) | MXPA04001812A (es) |
| NO (1) | NO20040866L (es) |
| NZ (1) | NZ531437A (es) |
| SE (1) | SE0102886D0 (es) |
| WO (1) | WO2003017982A1 (es) |
| ZA (1) | ZA200401085B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302824D0 (sv) * | 2003-10-24 | 2003-10-24 | Astrazeneca Ab | New use |
| CN103140243A (zh) * | 2010-08-09 | 2013-06-05 | 迪格玛斯玛特有限公司 | 益生菌液体食品 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
| GB8624213D0 (en) * | 1986-10-09 | 1986-11-12 | Sandoz Canada Inc | Sustained release pharmaceutical compositions |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| SE510305C2 (sv) * | 1997-05-30 | 1999-05-10 | Astra Ab | Nytt salt |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
-
2001
- 2001-08-29 SE SE0102886A patent/SE0102886D0/xx unknown
-
2002
- 2002-08-28 NZ NZ531437A patent/NZ531437A/en unknown
- 2002-08-28 WO PCT/SE2002/001540 patent/WO2003017982A1/en not_active Application Discontinuation
- 2002-08-28 CA CA002457339A patent/CA2457339A1/en not_active Abandoned
- 2002-08-28 MX MXPA04001812A patent/MXPA04001812A/es unknown
- 2002-08-28 HU HU0401587A patent/HUP0401587A3/hu unknown
- 2002-08-28 KR KR10-2004-7002919A patent/KR20040032976A/ko not_active Application Discontinuation
- 2002-08-28 JP JP2003522502A patent/JP2005504051A/ja active Pending
- 2002-08-28 EP EP02763154A patent/EP1423098A1/en not_active Withdrawn
- 2002-08-28 CN CNA028167104A patent/CN1547466A/zh active Pending
- 2002-08-28 BR BR0212166-2A patent/BR0212166A/pt not_active IP Right Cessation
- 2002-08-28 US US10/488,022 patent/US20040204482A1/en not_active Abandoned
- 2002-08-28 IL IL16037202A patent/IL160372A0/xx unknown
-
2004
- 2004-02-10 ZA ZA200401085A patent/ZA200401085B/xx unknown
- 2004-02-26 NO NO20040866A patent/NO20040866L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2457339A1 (en) | 2003-03-06 |
| NZ531437A (en) | 2005-12-23 |
| ZA200401085B (en) | 2005-06-22 |
| BR0212166A (pt) | 2004-07-13 |
| HUP0401587A3 (en) | 2007-03-28 |
| NO20040866L (no) | 2004-04-19 |
| WO2003017982A1 (en) | 2003-03-06 |
| IL160372A0 (en) | 2004-07-25 |
| US20040204482A1 (en) | 2004-10-14 |
| CN1547466A (zh) | 2004-11-17 |
| KR20040032976A (ko) | 2004-04-17 |
| EP1423098A1 (en) | 2004-06-02 |
| SE0102886D0 (sv) | 2001-08-29 |
| HUP0401587A2 (hu) | 2004-11-29 |
| JP2005504051A (ja) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| RS20050344A (en) | Treatment for hemorrhagic shock | |
| UA74337C2 (uk) | Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії | |
| HUP0103078A2 (hu) | Készítmények és eljárások szürkehályog kezelésére | |
| HK1068606A1 (en) | Novel aminobenzoephenones | |
| MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| MXPA04001805A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
| NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist | |
| MXPA04001812A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| HUP0204391A2 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
| SE0102888D0 (sv) | New formulation | |
| TW200502002A (en) | A new oral immediated release dosage form | |
| TW200619204A (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
| HK1075390A1 (en) | Citalopram for the treatment of elevated blood pressure | |
| DE60221104D1 (de) | Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose | |
| IL162391A0 (en) | Method of treatment | |
| NZ514490A (en) | Method and means for treating post-polio syndrome | |
| MXPA03010920A (es) | Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia. | |
| MX2022006535A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |